The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Result of venetoclax plus/minus azacitidine for R/R MDS
Amer Zeidan
• 8 Dec 2019
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated data from the ongoing phase 1b, open-label, multicenter study (NCT02966782) evaluating the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in relapsed/refractory myelodysplastic syndromes (MDS). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
